Wuxi Apptec China

Wuxi Apptec China company information, Employees & Contact Information

Established in December 2000, WuXi AppTec (NYSE: WX) is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform with operations in China and the United States. WuXi AppTec has successfully established a fully integrated services and technology platform during the past decade. The company built its initial capabilities around discovery chemistry and has further enhanced the integrated services with analytical services, bio-analytical services, process research, process development services, API manufacturing services, DMPK/ADME, discovery biology, pharmacology, formulation, toxicology, genomic services, biologics manufacturing services, antibody and biological research reagent manufacturing and sales, and most recently clinical research and regulatory services. WuXi AppTec has developed from four founders and a single laboratory in December 2000 to 10,000 employees and 5 million square feet of laboratory and manufacturing space, including facilities under construction. The company is actively improving its capabilities and capacity through new expansions in its global business. Capitalizing on the great advantage of conducting R&D services both in China and in the U.S., WuXi AppTec is building an alternative R&D engine to serve the global life-science industry. 药明康德新药开发有限公司于2000年12月成立,是全球领先的制药、生物技术以及医疗器械研发开放式能力和技术平台公司,在中美两国均有运营实体。 十多年来,药明康德成功打造了全方位一体化的研发服务技术平台。创建之初,药明康德凭借其在发现化学合成领域的雄厚实力实现了全面发展。近几年来,我们又新增了一系列一体化服务,包括分析服务、生物分析服务、工艺研究、工艺研发服务、API生产服务、药物代谢及其动力学服务、研发生物学、药理学、制剂、毒理学、基因组服务、生物制剂生产服务、抗体及生物诊断试剂的生产和销售服务以及临床研发和产品注册服务等。 从 2000 年 12 月创立至今,药明康德的员工数从4 人增长至 10000 人,实验室由当初仅有的一间增长到近46 万平方米已有及在建研发基地和生产厂房。与此同时,药明康德还在不断增强服务能力,拓宽服务领域,以更好地服务公司持续增长的全球业务需求。作为一家全球领先的医药研发服务公司,药明康德将继续致力于在中美两国为全球客户提供高质量的医药研发服务,帮助研发出更多造福患者的新药及产品。

Company Details

Employees
520
Address
Shanghai, Cn
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
HQ
Shanghai
Looking for a particular Wuxi Apptec China employee's phone or email?

Wuxi Apptec China Questions

News

WuXi AppTec Marks 25 Years as a Trusted Partner in Global Drug Discovery, Development, and Manufacturing - Reuters

WuXi AppTec Marks 25 Years as a Trusted Partner in Global Drug Discovery, Development, and Manufacturing Reuters

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year - Yahoo Finance

WuXi AppTec Awarded Gold Medal by EcoVadis Sustainability Rating for Second Consecutive Year Yahoo Finance

Unlocking Europe's Pharma Potential: How WuXi AppTec Bridges the Innovation-to-Market Gap - openPR.com

Unlocking Europe's Pharma Potential: How WuXi AppTec Bridges the Innovation-to-Market Gap openPR.com

RMB6.88B Returned to Shareholders: WuXi AppTec's Massive Dividend & Buyback Plan Hits 70% of 2024 Profit - Stock Titan

RMB6.88B Returned to Shareholders: WuXi AppTec's Massive Dividend & Buyback Plan Hits 70% of 2024 Profit Stock Titan

A Concise Flow Synthesis of the IKZF2 Glue Degrader DKY709 - ACS Publications

A Concise Flow Synthesis of the IKZF2 Glue Degrader DKY709 ACS Publications

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends - The Manila Times

WuXi AppTec Implements Its First Interim Dividend Plan, Distributing RMB1.03 Billion in Cash Dividends The Manila Times

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research - Business Wire

NAMSA Acquires the U.S. Medical Device Testing Operations of WuXi AppTec, Solidifying its Position as the Leader in MedTech Testing and Clinical Research Business Wire

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity - WuXi AppTec

WuXi AppTec Nantong Site Receives 2025 Architizer A+Award for Its Unique Blend of Technology and Humanity WuXi AppTec

How WuXi AppTec Embeds Quality: A Global Blueprint for Trust and Excellence - openPR.com

How WuXi AppTec Embeds Quality: A Global Blueprint for Trust and Excellence openPR.com

DNA-Compatible Huisgen [3 + 2] Cycloaddition of In Situ Formed Nitrile Oxides with Alkenes or Alkynes to Synthesize Isoxazolines or Isoxazoles - ACS Publications

DNA-Compatible Huisgen [3 + 2] Cycloaddition of In Situ Formed Nitrile Oxides with Alkenes or Alkynes to Synthesize Isoxazolines or Isoxazoles ACS Publications

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health - PR Newswire

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health PR Newswire

WuXi AppTec's New EU Batch Release Services: What This Means for European Biotech - openPR.com

WuXi AppTec's New EU Batch Release Services: What This Means for European Biotech openPR.com

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025 - Yahoo Finance

WuXi AppTec Issues Positive Profit Alert for the First Half of 2025 Yahoo Finance

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers - WuXi AppTec

WuXi AppTec Breaks Ground on New Site in Singapore to Better Support Global Customers WuXi AppTec

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY - Yahoo Finance

WuXi AppTec Achieves Strong Growth in Revenue and Profit for Q2 and H1 2025, H1 Revenue from Continuing Operations[1] Up 24.2% YoY, and Adjusted Non-IFRS Net Profit Up 44.4% YoY; Backlog for Continuing Operations Up 37.2% YoY Yahoo Finance

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services - WuXi AppTec

WuXi AppTec Expands Site in California for Pharmaceutical R&D Services WuXi AppTec

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY - Yahoo Finance

WuXi AppTec Q1 2025 Revenue, Profit Resume Double Digit Growth, Revenue Up 21.0% YoY, Adjusted Non-IFRS Net Profit Up 40.0% YoY; Backlog for Continuing Operations Up 47.1% YoY Yahoo Finance

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange - WuXi AppTec

WuXi AppTec Lists H Shares on the Hong Kong Stock Exchange WuXi AppTec

WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results - WuXi AppTec

WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results WuXi AppTec

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections - PR Newswire

WuXi AppTec's Changzhou and Taixing API Sites Successfully Pass FDA Inspections PR Newswire

WuXi AppTec (603259): Company Profile, Stock Price, News, Rankings - Fortune

WuXi AppTec (603259): Company Profile, Stock Price, News, Rankings Fortune

Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space - ACS Publications

Highly Selective Novel Heme Oxygenase-1 Hits Found by DNA-Encoded Library Machine Learning beyond the DEL Chemical Space ACS Publications

WuXi AppTec Announces Record-Breaking 102% Profit Surge: Strong Growth Across All Metrics - Stock Titan

WuXi AppTec Announces Record-Breaking 102% Profit Surge: Strong Growth Across All Metrics Stock Titan

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region - PR Newswire

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region PR Newswire

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland - Bristol Myers Squibb

WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, Switzerland Bristol Myers Squibb

RMB5.84B Shareholder Returns: WuXi AppTec Completes Second RMB1B Buyback, Returns 60% of 2024 Profits - Stock Titan

RMB5.84B Shareholder Returns: WuXi AppTec Completes Second RMB1B Buyback, Returns 60% of 2024 Profits Stock Titan

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma - PR Newswire

WuXi Advanced Therapies Receives FDA Approval to Manufacture Iovance's AMTAGVI™ (lifileucel) for Advanced Melanoma PR Newswire

DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles and 1,2,4-Triazoles - ACS Publications

DNA-Compatible Cyclization Reaction to Access 1,3,4-Oxadiazoles and 1,2,4-Triazoles ACS Publications

WuXi AppTec Receives AA ESG Rating from MSCI - PR Newswire

WuXi AppTec Receives AA ESG Rating from MSCI PR Newswire

Triaging of DNA-Encoded Library Selection Results by High-Throughput Resynthesis of DNA–Conjugate and Affinity Selection Mass Spectrometry - ACS Publications

Triaging of DNA-Encoded Library Selection Results by High-Throughput Resynthesis of DNA–Conjugate and Affinity Selection Mass Spectrometry ACS Publications

William Blair and BDA advise BMS on sale of its Couvet, Switzerland facility to WuXi AppTec - BDA Partners

William Blair and BDA advise BMS on sale of its Couvet, Switzerland facility to WuXi AppTec BDA Partners

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services - PR Newswire

WuXi AppTec Expands Site in the U.S. for Drug Development Testing Services PR Newswire

NEOM and WuXi AppTec sign strategic MoU to advance Saudi Arabia’s biotech sector - ZAWYA

NEOM and WuXi AppTec sign strategic MoU to advance Saudi Arabia’s biotech sector ZAWYA

1,2,3‐Triazole hybrids with anti‐HIV‐1 activity - Feng - 2021 - Archiv der Pharmazie - Wiley Online Library

1,2,3‐Triazole hybrids with anti‐HIV‐1 activity - Feng - 2021 - Archiv der Pharmazie Wiley Online Library

WuXi AppTec Appoints Edward Hu as Co-CEO - PR Newswire

WuXi AppTec Appoints Edward Hu as Co-CEO PR Newswire

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health - bastillepost.com

WuXi AppTec Looks to Extend CRDMO Platform to Saudi Arabia as It Signs Strategic MoUs with NEOM and Ministry of Health bastillepost.com

WuXi STA Changzhou Site Passes First U.S. FDA Inspection - 美通社

WuXi STA Changzhou Site Passes First U.S. FDA Inspection 美通社

Wuxi Pharmatech Well Positioned To Continue Growing As Independent Company; Will Receive Breakup Fee Of $30M - Pharmaceutical Online

Wuxi Pharmatech Well Positioned To Continue Growing As Independent Company; Will Receive Breakup Fee Of $30M Pharmaceutical Online

WuXi AppTec’s Global Footprint: Serving Partners Across Asia, Europe, and North America - isStories

WuXi AppTec’s Global Footprint: Serving Partners Across Asia, Europe, and North America isStories

WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth - isStories

WuXi AppTec: Integrating in Local European Ecosystems for Sustainable Growth isStories

How WuXi AppTec’s CRDMO Model Drives Business Growth - isStories

How WuXi AppTec’s CRDMO Model Drives Business Growth isStories

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant